Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative market for pharmacotherapies owing to the lack of approved agents and the disease’s prevalence. The body of evidence for the financial costs of the disease is growing, particularly with respect to cardiovascular (CV) disease, liver failure, and the fact that NASH will soon become the leading reason for liver transplantation. The lack of treatment options and the limited awareness of the disease and its complications have resulted in low diagnosis and treatment rates. However, as education increases, novel diagnostic tools are developed, and new therapies are approved, diagnosis and treatment rates will increase, driving growth of the market overall. Currently, despite guidelines recommending certain off-label medications, prescribing is usually limited to specialists caring for patients with more-advanced disease. However, as education increases, novel diagnostic tools are developed, and approved medical therapies become available, diagnosis and treatment rates will increase and drive growth of the market overall.Questions Answered: What is the prevalence of NASH, and what is driving the growth of this indication? How is NASH being managed? With no approved medications, how are physicians using available prescription medications off-label to treat the disease? Which emerging therapy will gain the greatest share in the nascent branded therapy market? Where will obeticholic acid, elafibranor, cenicriviroc, and resmetirom fit into the evolving NASH treatment paradigm?Geographies:United States, France, Germany, Italy, Spain, United Kingdom, JapanKey companies mentioned: Intercept Pharmaceuticals, Gilead, Genfit, Allergan, Galectin Therapeutics, Galmed Pharmaceuticals, Madrigal Pharmaceuticals, Viking Therapeutics, Cirius Therapeutics, NGM Bio, Novo Nordisk, Novartis, Bristol-Myers Squibb, Enanta PharmaceuticalsKey drugs covered: Obeticholic acid, elafibranor, cenicrivirox, belapectin (GR-MD-02), resmetirom (MGL-3196), aramchol, VK-2809, MSDC-0602K, pegbelfermin (BMS-986036), aldafermin (NGM282), cilofexor, EDP-305, semaglutide, firsocostat, vitamin E, pioglitazone.